
Oncology NEWS International
- Oncology NEWS International Vol 16 No 8
- Volume 16
- Issue 8
Avalon initiates phase II trial of AVN944 in pancreatic cancer
Avalon initiates phase II trial of AVN944 in pancreatic cancer
GERMANTOWN, MarylandAvalon Pharmaceuticals, Inc. has initiated a phase II clinical trial of AVN944 in combination with gemcitabine (Gemzar) in patients with newly diagnosed pancreatic cancer. After a dose-escalation phase, approximately 110 to 120 patients will be enrolled in an efficacy and safety phase. AVN944 is an oral small molecule agent that inhibits inosine monophosphate dehydrogenase (IMPDH), an enzyme that is critical for cells to be able to synthesize guanosine triphosphate (GTP), a molecule required for DNA synthesis and cellular signaling.
Articles in this issue
almost 19 years ago
Avoiding copay shockalmost 19 years ago
Induction chemo increases survival in unresectable NSCLCalmost 19 years ago
Superselective chemo strategies for HCCalmost 19 years ago
'Value meal dosing' of lapatinib is proposedalmost 19 years ago
AMA approves CPT code for Axxent electronic brachytherapyalmost 19 years ago
Zevalin/R after CHOP-R doubles CRs in follicular NHLalmost 19 years ago
RT plus local paclitaxel gel promising in esophageal caalmost 19 years ago
GeneSearch BLN Assay gets FDA approval for node assessment during surgeryalmost 19 years ago
TH vs TCH in metastatic breast cancer: 'Take your pick'




















































